Hematopoiesis

Blood Stem Cell & Lineages

May 18, 2009

How to increase hematopoietic stem cell engraftment and transplant outcome?

In business, educational | 3 comments | permalink

Written by
Alex

Print This Post
The most significant limitation of using of hematopoietic stem cell transplantation for treatment hematological and non-hematological diseases is a low number of progenitor/stem cells in the graft. For sufficient engraftment and good clinical outcome 2-5 millions of CD34+ cells should be transplanted. Unfortunately, many cell products, especially cord blood samples contain less number of stem cells than required.

Here I was trying to summarize some approaches used for improvement of engraftment by mostly increasing stem cell number per graft. The top part of the table represents approaches which have a potential to be commercialized.

approach
 examples
 references
 phase
Increase yield of HSC by isolation procedure
 1. cord + placental blood HSC

2. improving CB processing

 1. HemaCell Perfusion system



2. BioE PrepaCyte-CB

 preclinical - phase I
HSC expansion ex vivo
 using cytokine cocktails or “artificial niche” bioreactors StemEx Gamida Cell phase II-III
co-transplantation with cells increasing engraftment
 1. myeoid progenitors

2. mesenchymal cells

 1. Cellerant CLT-08

2. Pluristem PLX-I

1. phase I



2. preclinical - phase I
co-transplantation with few HSC sources
 1. double (multiple) unit CB

2. CB + MB of BM from 3rd party donors

 1. NCT00514579



2. Bone Marrow Transplant 2009; 43: 365

 1. phase II-III



2. phase I
new conditioning regiments
 making more niches available in host BM Science 2007; 5854: 1296 preclinical
new routes to transplantation of HSC intra-bone bone marrow transplant Lancet Oncology 2008;9:831 phase I-II

CB - cord blood; BM - bone marrow; MB - mobilized blood



Let me know if I missed something.

Enter your email address:

Delivered by FeedBurner

Post to Twitter

email this | tag this | digg this | trackback | comment RSS feed

3 comments for this post.

  1. Comment from Denis on May 18th, 2009 :

    it was writen to test new option - ‘tweet this’
    :)

  2. Comment from Jim H on May 18th, 2009 :

    Alex,

    Actually, LifeBankUSA (a subsidiary of Celgene) is in Clinical trial (I believe phase I) with their combined placenta + CB transplants: see http://www.lifebankusa.com/moretreatment-success.html and http://www.celgene.com/pdfs/product_pipeline.pdf

  3. Comment from Alex on May 18th, 2009 :

    thanks Jim,
    I’ve heard that Cryo-Cell proposed to mix CB with menstrual blood, I don’t know how that’s going to work.

    to Denis -
    no, not only because of that :)) I had this post in mind for a long while.

Leave a Comment